920979-07-3 Usage
Molecular structure
1H-Pyrrolo[3,2-b]pyridine-2-carboxylic acid, 1-[(3-fluorophenyl)methyl]-5-(trifluoromethyl)-, ethyl ester has a pyrrolopyridine core, a trifluoromethyl group, and an ethyl ester moiety.
Fluorophenyl group
Contains a 3-fluorophenyl group, which is a structural motif commonly found in pharmaceutical compounds.
Trifluoromethyl group
Contains a 5-trifluoromethyl group, which is an important structural motif in medicinal chemistry.
Ethyl ester moiety
The presence of an ethyl ester moiety provides the compound with a lipophilic nature, enhancing its solubility in organic solvents and potentially improving its bioavailability.
Pharmaceutical applications
Commonly used as a precursor in the development of potential drug candidates, particularly in the design of new treatments for various medical conditions.
Medicinal chemistry
The compound's structural motifs, such as the pyrrolopyridine core, trifluoromethyl group, and ethyl ester moiety, make it a valuable compound in medicinal chemistry research.
Check Digit Verification of cas no
The CAS Registry Mumber 920979-07-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,0,9,7 and 9 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 920979-07:
(8*9)+(7*2)+(6*0)+(5*9)+(4*7)+(3*9)+(2*0)+(1*7)=193
193 % 10 = 3
So 920979-07-3 is a valid CAS Registry Number.
920979-07-3Relevant academic research and scientific papers
N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy
-
Page/Page column 20, (2010/03/04)
The invention relates to compounds of the general formula (I): Wherein X, Y, Z, Z1, Z2, Z3, Z4 and n are as defined herein. The invention also relates to a method for making the same and to the use thereof in th
N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
-
Page/Page column 16-17, (2008/12/05)
The invention concerns compounds of general formula (I), wherein n, the pyrrolopyridine ring, X, Z1, Z2, Z3, Z4, Z5 and W are as defined herein. The invention also concerns a method for preparing said compounds and their therapeutic use.
